Since acquiring Protana in November 2005, Transition Therapeutics has been using the company's Optimol technology to identify small molecules that have affinities to selected protein targets, including targets related to hypertension, anemia, and Alzheimer's disease, according to a person familiar with the developments. Protana's proteomics-based biomarker discovery business, in the meantime, has been abandoned.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.